EnteroMedics
EnteroMedics was a Saint Paul-based medical device company (founded 2002) that developed implantable vagus nerve stimulation therapies targeting obesity and related metabolic conditions, serving patients and healthcare providers in the broader internal neuromodulation market.
- Company typePrivate
- Founded2002
- HeadquartersSaint Paul, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What EnteroMedics does
EnteroMedics Inc. (formerly NASDAQ: ETRM) was a Saint Paul, Minnesota-based medical device company founded in 2002, operating with 11-50 employees and focused on developing neuromodulation therapies for obesity and obesity-related metabolic conditions. The company's core technology centered on vagus nerve stimulation (commonly branded as vBloc), an implantable neuromodulation platform positioned within the broader internal neuromodulation devices market, where it competed against materially larger incumbents including Medtronic, Boston Scientific, and Nevro Corp. The addressable market was sizable: the internal neuromodulation devices segment was projected to reach $4.24B by 2030 at a 9.2% CAGR, and the vagus nerve stimulation market was projected to grow from $10.67B in 2024 to $23.73B by 2031 at a 10.50% CAGR.
The company's product and revenue model is not fully detailed in the source material. No pricing, reimbursement, sales channel, or unit-shipment data is disclosed, and no revenue figure is available. The customer base is described as spanning obesity-treatment patients, patients with neurological disorders treatable by vagus nerve stimulation (epilepsy, depression, migraine, chronic pain), and the healthcare providers who implant the device, implying a B2B2C commercial model in which physician adoption drives patient throughput. The company funded its operations through at least ten disclosed funding rounds totaling roughly $160M+ between 2004 and 2017, with the 2017 cohort (~$100.1M across four rounds) coinciding with two acquisitions: BarioSurg (May 2017, undisclosed) and ReShape Lifesciences (October 2017, $61M), the latter signaling a pivot toward a broader bariatric device portfolio. Investors included Aberdare Ventures, Bay City Capital, and MPM Capital (2010 round). The company is now delisted from NASDAQ and its corporate domain has been redirected to unrelated content, indicating that the original operating entity is no longer active in its prior form; the analysis here describes the company as it existed through 2017.
EnteroMedics firmographics
Firmographics- Name
- EnteroMedics
- Website
- https://enteromedics.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EnteroMedics was a Saint Paul-based medical device company (founded 2002) that developed implantable vagus nerve stimulation therapies targeting obesity and related metabolic conditions, serving patients and healthcare providers in the broader internal neuromodulation market.
- Ownership category
- akta.pro rank
EnteroMedics industry classification
Industry- Product category
- Bariatric / Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
Keywords
Where EnteroMedics is headquartered
LocationHeadquarters
- HQ city
- Saint Paul
- HQ country
- United States
- HQ region
- North America
Markets served
EnteroMedics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
EnteroMedics product offering
Product offeringCore offering
EnteroMedics develops and commercializes implantable vagus nerve stimulation (vBloc) medical devices for the treatment of obesity and obesity-related risk factors. The company's neuromodulation systems are deployed internally in patients and used by healthcare providers as a non-pharmaceutical alternative for weight management and metabolic control.
Differentiator
Problem solved
Functional benefit
Products and services
- vBloc / Vagus Nerve Stimulation (VNS) Neuromodulation System
- Vagus Nerve Stimulation Therapy (Neurological Indications)
Quantifiable outcome
- The internal neuromodulation devices market is projected to reach $4.24 billion by 2030 with a CAGR of 9.2%
- +1 more outcomes
Companies that use EnteroMedics
Customer profileSegments3 records
Ideal customer profiles2 records
EnteroMedics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EnteroMedics partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights4 records
EnteroMedics competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Global medical device leader with a broad neuromodulation portfolio including VNS (for epilepsy and depression), DBS, SCS, and PNS. Direct competitor to EnteroMedics across the implantable neurostimulation category with far greater scale and commercial reach.
- Boston Scientific: Large diversified medtech with significant neuromodulation and spinal cord stimulation franchises. Competes in the same implantable neurostimulation market as EnteroMedics with extensive hospital sales coverage.
- Stryker: Large diversified medtech with surgical, orthopedic, and neuromodulation-adjacent businesses. Relevant as a potential strategic acquirer of obesity/neurostim assets and as an incumbent in adjacent device categories.
Direct peers
- Nevro Corp: Pure-play implantable neuromodulation company (10 kHz HF10 therapy for chronic pain). Directly comparable to EnteroMedics as a focused neurostim device company competing against large incumbents.
- LivaNova: Owns the legacy Cyberonics VNS franchise (VNS Therapy) for epilepsy and depression, the closest direct competitor to EnteroMedics' vagus nerve stimulation platform.
- Inspire Medical Systems: Developer of an implantable neurostimulation device (hypoglossal nerve stimulation) for obstructive sleep apnea. Comparable as a small-cap, focused implantable neurostim company that scaled into a commercial leader.
- ReShape Lifesciences: Bariatric and obesity device company (Lap-Band, ReShape Balloon, vBloc) that was acquired by EnteroMedics in 2017. Direct overlap in the obesity device category and historical peer.
- Apollo Endosurgery: Developer of endoscopic weight loss solutions (Orbera intragastric balloon, OverStitch suturing system). Direct peer in the non-surgical bariatric and obesity device market.
Emerging players
- NeuroPace: Developer of the RNS System, a closed-loop implantable neurostim for epilepsy. Comparable in scale, technology category (implantable neurostim), and indication overlap to EnteroMedics.
- electroCore: Developer of non-invasive vagus nerve stimulation (gammaCore) for migraine and cluster headache. Adjacent VNS-focused peer sharing target indications with EnteroMedics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
EnteroMedics social profiles
Digital presenceEnteroMedics financial estimates
Financial estimateRevenue estimate
Valuation estimate
EnteroMedics leadership team
Management profileNumber of profiles
Profiles4 records
EnteroMedics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EnteroMedics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EnteroMedics
What does EnteroMedics do?
EnteroMedics develops and commercializes implantable vagus nerve stimulation (vBloc) medical devices for the treatment of obesity and obesity-related risk factors. The company's neuromodulation systems are deployed internally in patients and used by healthcare providers as a non-pharmaceutical alternative for weight management and metabolic control.
Is EnteroMedics a public or private company?
EnteroMedics is a private company. It is classified as unknown and is currently operating.
When was EnteroMedics founded?
EnteroMedics was founded in 2002. It employs 11 to 50 people.
Where is EnteroMedics based?
EnteroMedics is headquartered in Saint Paul, United States, in the North America region.
Who are EnteroMedics's main competitors?
Broad incumbents on record are Medtronic, Boston Scientific and Stryker. Direct peers are Nevro Corp, LivaNova, Inspire Medical Systems, ReShape Lifesciences and Apollo Endosurgery. Emerging players are NeuroPace and electroCore.
Does EnteroMedics have an API?
No public API is recorded for EnteroMedics.
What industry is EnteroMedics in?
EnteroMedics's product category is Bariatric / Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.